Know Cancer

forgot password

A Phase II Trial of Lapatinib and Capectiabine for Patients With Refractory Advanced Colorectal Adenocarcinoma (LAP109859)

Phase 2
18 Years
Not Enrolling
Metastatic Colorectal Cancer

Thank you

Trial Information

A Phase II Trial of Lapatinib and Capectiabine for Patients With Refractory Advanced Colorectal Adenocarcinoma (LAP109859)

1. To evaluate the response rate of lapatinib and capecitabine combination in patients
with metastatic colon or rectal cancer.

2. To evaluate the toxicity and tolerability of lapatinib and capecitabine in this

3. To determine overall survival and disease free survival of lapatinib and capecitabine.

Inclusion Criteria:

- Age > 18 years

- Pathologically confirmed, locally advanced or metastatic adenocarcinoma of the colon
or rectum

- Patients must have had progression of disease on prior therapy with an
oxaliplatin-containing or irinotecan containing regimen

- Proper radiographic documentation of measurable disease using RECIST criteria

- ECOG performance status (PS) of 0 or 1

- Laboratory parameters:

Hgb: ≥ 9.0 g/dl ANC ≥ 1500/ul Platelet ≥ 100,000/ul Creatinine ≤ 2x ULN OR Creatinine
clearance ≥ 30 mg/ml Bilirubin ≤ 2x ULN AST ≤ 2x ULN or 5X ULN if liver metastases are

- Patient has signed informed consent

- Toxicities from prior therapy (except alopecia and neuropathy) must have resolved to
grade 1 or better prior to enrollment

Exclusion Criteria:

- Administration of more than one prior systemic chemotherapy for metastatic disease

- Pregnant or breast-feeding women: female patients must agree to use effective
contraception, must be surgically sterile, or must be postmenopausal. Male patients
must agree to use effective contraception or be surgically sterile. The definition
of effective contraception will be based on the judgment of the principal
investigator or a designated associate. All at-risk female patients must have a
negative serum pregnancy test within 7 days prior to randomization.

- Active inflammatory bowel disease, significant bowel obstruction, or chronic diarrhea
(grade 2).

- Known human immunodeficiency virus (HIV) positivity or
acquired-immunodeficiency-syndrome (AIDS)-related illness.

- No previous or concurrent malignancy is allowed except for adequately treated basal
cell or squamous cell skin cancer, in-situ cervical cancer, or other cancer for which
the patient has been disease-free for 3 years.

- Known CNS metastases

- Prior therapy which specifically and directly targets the EGFR pathway

- Significant history of uncontrolled cardiovascular disease, defined as:

- History of uncontrolled or symptomatic angina

- History of arrhythmias requiring medications, or clinically significant, with
the exception of asymptomatic atrial fibrillation requiring anticoagulation

- Myocardial infarction < 6 months prior to study entry

- Cerebrovascular accident <6 months prior to study entry

- Uncontrolled or symptomatic congestive heart failure

- Ejection fraction below the institutional normal limit

- Any other cardiac condition, which in the opinion of the treating physician,
would make this protocol unreasonably hazardous for the patient

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

response to therapy

Outcome Time Frame:

evaluate every 9 weeks (or every 3 cycles)

Safety Issue:


Principal Investigator

Alcee J Jumonville, M.D.

Investigator Role:

Study Chair

Investigator Affiliation:

Gunderson Lutheran - LaCrosse


United States: Institutional Review Board

Study ID:

CO07201 (LAP109859)



Start Date:

September 2007

Completion Date:

August 2009

Related Keywords:

  • Metastatic Colorectal Cancer
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Colorectal Neoplasms



University of Wisconsin Paul P. Carbone Comprehensive Cancer Center Madison, Wisconsin  53792-6164